Samsrita Labs Announces Key Director Appointments and Proposed Capital Reduction Scheme

Samsrita Labs Announces Key Director Appointments and Proposed Capital Reduction Scheme​

Samsrita Labs Limited has reported significant outcomes following its Board meeting held on July 4, 2026. The company approved the appointment of two new Additional Directors and proposed a scheme for the reduction of its issued share capital. Furthermore, the board considered several crucial changes to the Memorandum of Association and related party transactions.

The Board approved the appointment of Mr. Ravi Kanth Naga Pattabhi Chopperla as an Additional Director in the Professional and Non-Executive category, effective July 4, 2026. Additionally, Mr. Satyanarayana Murthy Varanasi was appointed as an Additional Director in the Independent category for a period of five years, also effective from the same date, pending shareholder approval.

The appointments bring together experienced leadership to the company. Ravi Kanth Chopperla brings over 18 years of experience in corporate advisory and investor relations, currently serving as Executive Director & Chief Operating Officer of QROPS Advisory Services Private Limited. Satyanarayana Murthy Varanasi has extensive background in defence, aviation, maritime operations, and legal practice before the High Court of Telangana.

The details concerning the newly appointed directors are summarized below:

Proposed Scheme for Capital Reduction​

The Board also proposed a scheme for the reduction and reorganization of the company’s capital under Section 66 read with Section 52 of the Companies Act, 2013. This scheme involves the cancellation and extinguishment of 11,37,48,550 fully paid-up equity shares of ₹10 each on a pro rata basis.

The capital reduction is designed to realign the equity structure of Samsrita Labs Limited and set off accumulated losses from prior years, totaling ₹11,57,66,110/-. The proposed scheme will reduce the company’s paid-up equity share capital from 22,74,97,100/-, comprising 2,27,49,710 equity shares of ₹10 each, to 11,37,48,550/-, comprising 1,13,74,855 equity shares of ₹10 each.

Following the cancellation, the company intends to set off the amount of ₹11,37,48,550/- against the total accumulated losses and share premium balance, which amounts to ₹11,57,66,110/-. The restructuring is intended to simplify the capital structure and improve the net worth by eliminating a substantial portion of past losses without impacting the economic interests of existing shareholders.

Business Expansion and General Matters​

The company also approved an alteration of its Main Object Clause in the Memorandum of Association. The change involves inserting a new clause allowing the company to engage in pet animal healthcare and wellness. This includes establishing, managing, and providing veterinary, diagnostic, preventive, curative, and therapeutic services for pets and companion animals. Furthermore, Samsrita Labs will manufacture, formulate, and deal in veterinary medicines, pet foods, nutraceuticals, medical devices, and related products.

Other material matters approved by the Board included:

• A proposal to enter into Related Party Transactions with QROPS Advisory Services Private Limited.
• The Directors Report for the Financial Year 2025-26.
• Scheduling an Annual General Meeting (AGM) for FY 2025-26 on Monday, August 10, 2026, through video conference or other Audio visual means (OAVM). The cut-off date for the AGM is set as Monday, August 3, 2026.

Stock Price Movement​

Samsrita Labs Ltd. shares closed at ₹12.63 on Tuesday, ticking up 2.85% in post-market trading. The stock navigated an intraday range, moving between a low of ₹12.05 and a high of ₹12.89 during the session.